Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 15/20 | 0.49 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.43 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | IL6 | P05231 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10085239 | 0.85 | NUDT1 (0.63) | TLR7NUDT1IL6 | |
| SCHEMBL823233 | 0.79 | TLR7 (0.48) | TLR7YTHDC1NUDT1 | |
| SCHEMBL14944669 | 0.73 | BRD4 (0.48) | TLR7YTHDC1BRD4P2RX7 | |
| SCHEMBL14944672 | 0.72 | BRD4 (0.44) | TLR7YTHDC1BRD4P2RX7 | |
| SCHEMBL10085237 | 0.67 | EGLN2 (0.37) | YTHDC1BRD4 | |
| SCHEMBL3495412 | 0.66 | BRD4 (0.48) | TLR7BRD4P2RX7 | |
| SCHEMBL29997135 | 0.65 | TLR7 (0.82) | TLR7NUDT1IL6 | |
| SCHEMBL43878 | 0.65 | TLR7 (0.82) | TLR7NUDT1IL6 | |
| SCHEMBL18207825 | 0.65 | TLR7 (0.43) | TLR7TLR8 | |
| SCHEMBL2913478 | 0.64 | TLR7 (0.74) | TLR7NUDT1TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009247-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC (GB) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009247-A1 | PHOSPHOLIPID DRUG ANALOGS | PHOSPHO1, PXMP4, SGMS1 | TLR7 1935/4885YTHDC1 4672/4885NUDT1 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.